| Symbol | INKT |
|---|---|
| Name | MINK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 149 FIFTH AVENUE,SUITE 500, NEW YORK, New York, 10010, United States |
| Telephone | +1 212 994-8250 |
| Fax | — |
| — | |
| Website | https://www.minktherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001840229 |
| Description | MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. Additional info from NASDAQ: |
Ryan Barbara 🔴 sold 1.5K shares of MiNK Therapeutics, Inc. (INKT) at $12.80 Transaction Date: Jun 04, 2026 | Filing ID: 260084
Read moreHolcomb John Bradley 🟢 acquired 2.3K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253474
Read moreRyan Barbara 🟢 acquired 3.1K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253470
Read moreCorvese Brian 🟢 acquired 3.1K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253468
Read moreBehner Peter 🟢 acquired 2.8K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253466
Read moreWIINBERG ULF 🟢 acquired 2.4K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253461
Read moreMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
Read moreMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
Read more